AI Echocardiographic Screening of Cardiac Amyloidosis
Launched by CEDARS-SINAI MEDICAL CENTER · Oct 28, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients receiving an echocardiogram that is determined to be suspicious by EchoNet-LVH
- Exclusion Criteria:
- • Patients that decline consent
- • Patients receiving an echocardiogram that is determined to be not suspicious by EchoNet-LVH
About Cedars Sinai Medical Center
Cedars-Sinai Medical Center is a renowned nonprofit academic medical center located in Los Angeles, California, recognized for its commitment to patient care, research, and education. As a leading institution in clinical trials, Cedars-Sinai harnesses innovative approaches to advance medical knowledge and improve treatment outcomes across various specialties. With a multidisciplinary team of experts, state-of-the-art facilities, and a patient-centered approach, Cedars-Sinai actively contributes to the development of novel therapies and interventions, ensuring the highest standards of clinical research while prioritizing patient safety and ethical considerations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Portland, Oregon, United States
Los Angeles, California, United States
Palo Alto, California, United States
Chicago, Illinois, United States
Patients applied
Trial Officials
David Ouyang, MD
Principal Investigator
Cedars-Sinai Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported